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There is a large body of evidence that infection with the Epstein-Barr virus (EBV), the aetiological agent of 
infectious mononucleosis, has a role in the pathogenesis of many human chronic autoimmune diseases. This 
chapter will review the evidence for the role of EBV in each of these diseases and also focus on the features 
that are common to the different human chronic autoimmune diseases, with the aim of providing an 
explanation for what appears to be a unique role for EBV in the pathogenesis of these diseases. 
 
2. GENERAL ASPECTS OF HUMAN CHRONIC AUTOIMMUNE DISEASES 
 
Human chronic autoimmune diseases share a number of common features. The various autoimmune 
diseases have similarities in their patterns of genetic susceptibility. The major histocompatibility complex 
(MHC) class II region contributes to this genetic susceptibility, and each autoimmune disease is associated 
with particular MHC class II genes [1]. However, there is increasing evidence that another important 
genetic component is susceptibility to ‘autoimmunity-in-general’. People with one particular autoimmune 
disease such as multiple sclerosis (MS) have an increased risk of developing other autoimmune diseases, 
and their first-degree relatives also have an increased risk of developing other autoimmune diseases [2]. 
Studies on autoimmune family pedigrees have led to the proposal that autoimmunity is an autosomal 
dominant trait with penetrance (disease expression) in ∼92% of females and 49% of males carrying the 
abnormal gene [3, 4]. Furthermore, people with organ-specific autoimmune diseases, such as insulin-
dependent diabetes mellitus [5], autoimmune thyroid disease [6], MS [7] and inflammatory bowel disease 
[8] have an increased incidence of antinuclear antibodies. I have recently proposed that the genetic 
susceptibility to ‘autoimmunity-in-general’ is mediated by susceptibility to the effects of B-cell infection 
by EBV [9]. 
Human autoimmune diseases are generally more common in females than males and tend to be 
exacerbated in the post-partum period. Many chronic autoimmune diseases have a relapsing-remitting 
course, for example rheumatoid arthritis (RA), ulcerative colitis and MS, suggesting fluctuations in the 
autoimmune attack. Other autoimmune diseases, such as insulin-dependent diabetes mellitus and 
autoimmune hypothyroidism, do not become clinically apparent until much of the target organ has been 
destroyed; fluctuating autoimmune attack might also be occurring in these diseases but would not be 
clinically evident. Some chronic autoimmune diseases are manifested clinically by a primary progressive 
course, such as primary progressive MS, where there is progressive clinical deterioration without clear 
relapses or remissions. In such diseases there still could be fluctuations in the level of autoimmune attack 
but these could be masked by a lack of target organ repair and a subsequent lack of any periods of clinical 
improvement. There is also evidence of similarities in the environmental factors that predispose to or 
exacerbate different chronic autoimmune diseases; for example, exacerbations can be triggered by a variety 
of infections.  
 
3. GENERAL ASPECTS OF EBV INFECTION 
 
EBV has the unique ability to infect, activate and latently persist in B lymphocytes. When EBV infects 
resting B cells in vitro, it drives them into activation and proliferation independently of T-cell help. 
Infection of B cells from normal individuals in vitro results in the production of monoclonal 
autoantibodies reacting with antigens in multiple organs [10]. This accounts for the transient appearance of 
autoantibodies during the course of infectious mononucleosis [11]. Usually, the proliferating infected B 
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cells are eventually eliminated by EBV-specific cytotoxic CD8+ T cells, but latently infected non-
proliferating memory B cells persist in the individual for life [12]. Antigen-driven differentiation of latently 
infected memory B cells into plasma cells might trigger entry into the lytic cycle with the production of 
infectious virus [12]. 
 
4. POSSIBLE MECHANISMS BY WHICH EBV INFECTION COULD PROMOTE 
AUTOIMMUNE DISEASE 
 
EBV infection could promote autoimmune disease by: inducing cross-reactive immune responses against 
self antigens; infection of organs with resultant tissue damage and release of antigens and secondary 
immune sensitization; non-specific general upregulation of the immune system; infection of autoreactive B 
cells which could produce autoantibodies and act as professional antigen-presenting cells in the target 
organ. There is evidence for T-cell or antibody cross-reactivity between EBV antigens and self antigens, for 
example myelin basic protein in MS [13, 14], La antigen in Sjögren’s syndrome [15], SmD in systemic 
lupus erythematosus (SLE) [16] and self MHC-derived peptides in oligoarticular juvenile idiopathic 
arthritis [17]. However, cross-reactivity between self antigens and viral antigens is a phenomenon 
applicable to all infectious agents and is therefore unlikely to be the primary mechanism for the unique role 
that EBV appears to have in the pathogenesis of autoimmune diseases such as MS and SLE. Infection of 
organs with resultant tissue damage, release of antigens and secondary immune sensitization is also a 
mechanism that potentially could occur following infections with many different agents. Similarly, non-
specific general upregulation of the immune system, for example through upregulation of cytokines and 
adhesion molecules, could also occur following any infection. In contrast, the ability of EBV to infect and 
immortalize B cells, including autoreactive B cells, is unique and therefore a likely explanation for a unique 
pathogenic role of EBV in human chronic autoimmune diseases [9]. EBV-infected autoreactive B cells 
could produce pathogenic autoantibodies. They could also act as professional antigen-presenting cells in 
the target organ where they could provide a costimulatory survival signal to autoreactive T cells that have 
been activated in peripheral lymphoid organs by cross-reactivity with infectious agents and that would 
otherwise undergo activation-induced apoptosis when they enter the target organ [18-20]. On receiving a 
costimulatory survival signal from the EBV-infected B cells, the autoreactive T cells could instead 
proliferate and produce cytokines, which recruit other inflammatory cells, with resultant target organ 
damage and chronic autoimmune disease [9]. 
 
 
5. RELATIONSHIPS BETWEEN EBV INFECTION AND PARTICULAR 
AUTOIMMUNE DISEASES 
 
5.1. Multiple Sclerosis (MS) 
 
In 1980 Sumaya et al [21] reported a higher frequency of EBV seropositivity and a higher prevalence of 
high anti-EBV antibody titres in patients with MS compared to controls. Subsequent studies have shown 
that patients with MS are almost universally seropositive for EBV, raising the possibility that EBV infection 
might be a prerequisite for the development of MS. A review of eight published case-control studies 
comparing EBV serology in MS patients and controls revealed that 99% of MS patients were EBV-
seropositive compared to 90% of controls; the summary odds ratio of MS comparing EBV-seropositive 
individuals with EBV-seronegative individuals was 13.5 (95% confidence interval = 6.3-31.4) [22]. This 
difference does not apply to other herpes viruses [23]. Furthermore, a definite clinical history of infectious 
mononucleosis, which indicates primary infection with -EBV with a high frequency of infected B cells 
[11] further increases the risk of MS in EBV-seropositive subjects (eight-fold, if infection occurs before 
the age of 18 years) [24]. Levin et al [25], in a study of blood samples collected from US military 
personnel before the onset of MS, have shown that the presence of high titres of antibodies to EBV 
increases the risk 34-fold for developing MS. In some cases the first attack of MS has occurred at the time of 
primary EBV infection [26]. Interestingly, elevated anti-EBV antibody levels were found in a child who 
developed MS at the age of 10 months [27]. Anti-EBV antibodies occur more often in the cerebrospinal 
fluid (CSF) of MS patients than controls [28], but MS patients exhibit local central nervous system (CNS) 
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production of antibodies to various viruses [29]. Some patients have CSF oligoclonal bands of IgG reacting 
with EBV nuclear antigen-1 (EBNA-1) [30]. 
In 1979 Fraser et al [31] reported that patients with clinically active MS had an increased tendency to 
spontaneous in-vitro B-lymphocyte transformation compared to healthy subjects and patients with 
clinically quiescent MS. This could result from an increased frequency of circulating EBV-infected B cells 
or from defective control of outgrowth of EBV-transformed B cells in vitro by EBV-specific cytotoxic T 
cells. Wandinger et al [23] found EBV DNA in the sera of patients with clinically active MS but not in 
those with clinically stable disease. They interpreted this as evidence of an association between disease 
activity and EBV replication, which was supported by the finding of increased IgM and IgA responses to 
EBV early antigens in the patients with clinically active disease. Analysis of the CSF from MS patients 
using the polymerase chain reaction has not detected EBV DNA [32]; this makes it unlikely that EBV is a 
major target for immune attack in the CNS but does not exclude the presence of EBV-infected B cells that 
could act as professional antigen-presenting cells in the CNS. I have suggested [9] that EBV-infected B 
cells could be the source of the monoclonally expanded B cells present in the CSF of MS patients [33] and 
be responsible for the development of primary B-cell lymphoma in the CNS in MS [34]. 
Patients with MS have defective T-cell control of EBV-infected B cells [35]. One possible mechanism for 
this is decreased MHC class I expression on B cells, which has been reported to occur in patients with MS 
[36] and other autoimmune diseases [37], although it remains unclear whether the reported decrease is 
sufficient to cause decreased EBV-specific CD8+ T-cell cytotoxicity. A recent study found an increased 
frequency of CD8+ T cells responding to two immunodominant EBV epitopes in MS patients but it was 
not determined whether these T cells were cytotoxic [38]. EBV-specific CD8+ T cells are enriched in MS 
brain lesions compared to the peripheral blood, but such enrichment is also found for EBV-specific and 
cytomegalovirus-specific CD8+ T cells in other inflammatory lesions of the brain and other organs, 
including non-autoimmune inflammatory lesions [39]. This might simply reflect the accumulation of 
activated T cells in any chronic inflammatory lesion and does not necessarily imply that the virus-specific 
T cells are recognizing viral antigen or cross-reacting self antigen in the inflamed organ. 
There is evidence of T-cell cross-reactivity between EBV antigens and the myelin antigen, myelin basic 
protein [13]. A CD4+ T-cell clone from an MS patient has been found to react with both a DRB5*0101-
restricted EBV peptide and a DRB1*1501-restricted myelin basic protein peptide [14]. Furthermore, EBV 
infection induces the B-cell expression of αB-crystallin, a small heat-shock protein [40], which has been 
reported to be present in MS lesions and to be an immunodominant myelin antigen for T cells from healthy 
subjects and MS patients [41]. These findings have been interpreted as evidence that T cells generated in 
response to αB-crystallin expressed and presented by EBV-infected B cells might be pathogenic for CNS 
myelin expressing the same stress-induced protein [40]. 
 
5.2. Systemic Lupus Erythematosus (SLE) 
 
In 1971 Evans et al [42] reported elevated levels of anti-EBV antibodies in the sera of patients with SLE. 
Subsequent studies have shown that 99% of SLE patients are seropositive for EBV [43, 44]. The 
association of EBV-seropositivity with SLE is particularly striking in young patients, 99% of whom are 
seropositive compared to 70% of age-matched controls (odds ratio 49.9, 95% confidence interval 9.3-
1025, P < 0.00000000001) [43]. Seroconversion rates for other herpes viruses do not differ between SLE 
patients and controls [43, 44]. SLE can develop immediately after EBV-induced infectious mononucleosis 
[45]. T cells from patients with SLE cannot control the numbers of EBV-infected B cells from SLE 
patients or normal subjects but T cells from normal EBV-seropositive subjects can control infected B cells 
from SLE patients [46]; this indicates impaired T-cell control of EBV-infected B cells in SLE. This might 
be explained by the reported decrease in MHC class I expression on B cells in patients with SLE [37]. 
Patients with SLE have autoantibodies that bind an amino acid sequence which is shared between SmD, a 
small nuclear ribonucleoprotein, and EBNA-1 [16]. 
 
5.3. Rheumatoid Arthritis (RA) 
 
Patients with RA have increased anti-EBV antibody levels in their sera compared to healthy subjects [47]. 
They also have an increased frequency of circulating EBV-infected B cells, as determined by the fre-
quency of spontaneously transforming B cells [48]. A recent study using real-time polymerase chain 
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reaction has demonstrated a 10-fold increase in the EBV DNA load in the peripheral blood mononuclear 
cells of patients with RA compared to normal controls [49]. The high frequency of EBV-infected B cells in 
patients with RA is not due to increased uptake of the virus by B cells [48] but might be explained by the 
defective control of infected B cells by EBV-specific T cells [50, 51]. This might be explained by the 
reported decrease in MHC class I expression on B cells in patients with RA [37]. A study using a highly 
sensitive in-situ hybridization technique to detect EBV-encoded small nuclear RNAs (EBERs) in synovial 
membrane biopsy samples of patients with RA concluded that there was a lack of evidence for involvement 
of EBV [52]. Yet, the study actually found EBERs in seven (19%) of 37 patients with RA and in zero of 51 
patients with other joint diseases; cells expressing EBERs were B cells and plasma cells. These results 
could also be interpreted as supporting a role for EBV infection of B cells in the pathogenesis of RA if the 
negative results in the other patients with RA were due to the limitations imposed by sampling. EBV-
specific CD8+ T cells are enriched in the inflamed joints of patients with RA compared to the peripheral 
blood, but such enrichment is also found for cytomegalovirus-specific CD8+ T cells in the inflamed joints 
and for EBV-specific and cytomegalovirus-specific CD8+ T cells in autoimmune and non-autoimmune 
inflammatory lesions in other organs [39]. 
 
5.4. Sjögren’s Syndrome 
 
Patients with Sjögren's syndrome have increased levels of anti-EBV antibodies in their sera [53, 54], an 
increased tendency to spontaneous in-vitro B-lymphocyte transformation from the peripheral blood [54] 
and an increased frequency of shedding of EBV from the oropharynx [54]. They also have decreased EBV-
specific T-cell cytotoxicity [55] which accounts for the impaired ability to abort in-vitro outgrowth in 
regression assays of EBV-induced B-cell transformation [54, 55]. Decreased EBV-specific T-cell 
cytotoxicity might be explained by the reported decrease in MHC class I expression on B cells of patients 
with Sjögren’s syndrome [37]. EBV-infected B cells could be the source of the monoclonally expanded B 
cells in the salivary glands in Sjögren’s syndrome [56] and be responsible for the increased risk of the 
development of B-cell lymphoma in the salivary glands in Sjögren’s syndrome [57]. Moreover, antibodies 
to the La autoantigen of Sjögren’s syndrome also react with EBERs complexed with protein [15]. 
 
5.5. Autoimmune Thyroid Disease 
 
Patients with autoimmune thyroiditis have increased titres of anti-EBV antibodies in their sera compared to 
healthy subjects [58]. Thyrotoxicosis can develop immediately after infectious mononucleosis due to 
primary EBV infection, and autoimmune hypothyroidism can develop in association with acute EBV 
infection [59]. Intrathyroidal EBV-infected B cells could be the source of the monoclonally expanded B cells 
in the thyroid gland in autoimmune thyroiditis [60] and might be responsible for the increased risk of 




Patients with scleroderma have defective T-cell control of EBV-infected B cells [62]. Progressive systemic 
sclerosis has developed in an infant five months after infectious mononucleosis [63]. 
 
5.7. Autoimmune Liver Disease 
 
There is evidence for a role of EBV in both primary biliary cirrhosis and autoimmune hepatitis. Patients 
with primary biliary cirrhosis have increased levels of EBV DNA in their peripheral blood mononuclear 
cells, liver and saliva compared to controls [64]. They also have defective T-cell control of EBV-infected B 
cells [65]. Autoimmune hepatitis can develop soon after infectious mononucleosis due to primary EBV 
infection [66]. 
 
5.8. Inflammatory Bowel Disease 
 
Latently and productively EBV-infected B cells are present at a higher frequency in the colonic mucosa of 
patients with ulcerative colitis than controls [67, 68]. Patients with Crohn's disease also have a higher 
frequency of EBV-infected B cells in the colonic mucosa than controls [67]. 
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5.9. Cryptogenic Fibrosing Alveolitis 
 
Patients with cryptogenic fibrosing alveolitis have increased serum levels of antibodies against EBV, but 
not against herpes simplex virus or cytomegalovirus, compared to controls [69]. Furthermore, EBV DNA is 





There is a large body of evidence indicating that EBV infection has a major role in the pathogenesis of 
organ-specific and non-organ-specific human chronic autoimmune diseases. This evidence includes: a high 
frequency and high levels of circulating anti-EBV antibodies; triggering of the first attack of autoimmune 
disease by infectious mononucleosis due to primary EBV infection; an increased frequency of circulating 
EBV-infected B cells; defective T-cell control of EBV-infected B cells; an increased level of EBV DNA in 
target tissues; monoclonal B-cell expansion in the target organs; an increased risk of developing B-cell 
lymphoma in the target organs of chronic autoimmune disease; and T-cell and antibody cross-reactivity 
between EBV antigens and self antigens. These findings can be explained by the hypothesis that chronic 
autoimmune diseases occur in individuals genetically susceptible to the effects of B-cell infection by EBV, 
resulting in an increased frequency of latently EBV-infected autoreactive B cells. EBV-infected autoreactive 
B cells could produce pathogenic autoantibodies; they could also act as professional antigen-presenting 
cells in the target organ where they could provide a costimulatory survival signal to autoreactive T cells 
that have been activated in peripheral lymphoid organs by cross-reactivity with infectious agents and that 
would otherwise undergo activation-induced apoptosis in the target organ. On receiving a costimulatory 
survival signal from the EBV-infected B cells, the autoreactive T cells could proliferate and produce 
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